1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM
and Matrisian LM: Projecting cancer incidence and deaths to
2030: The unexpected burden of thyroid, liver, and pancreas
cancers in the United States. Cancer Res 74: 2913‑2921, 2014.
2. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC and Choi KW:
Clinical usefulness of carbohydrate antigen 19‑9 as a screening
test for pancreatic cancer in an asymptomatic population.
J Gastroenterol Hepatol 19: 182‑186, 2004.
3. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF and
Lin JT: Low efficacy of serum levels of CA 19‑9 in prediction
of malignant diseases in asymptomatic population in Taiwan.
Hepatogastroenterology 53: 1‑4, 2006.
4. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M,
Hruban RH, Eshleman JR, Nowak MA, et al: Distant metastasis
occurs late during the genetic evolution of pancreatic cancer.
Nature 467: 1114‑1117, 2010.
5. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP
and James RJ: Reduced accumulation of specific microRNAs in
colorectal neoplasia. Mol Cancer Res 1: 882‑891, 2003.
6. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S,
Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA
gene expression deregulation in human breast cancer. Cancer
Res 65: 7065‑7070, 2005.
7. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R,
Cheng A, Labourier E, Reinert KL, Brown D and Slack FJ: RAS is
regulated by the let‑7 microRNA family. Cell 120: 635‑647, 2005.
8. Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M,
Borges M and Goggins M: Pancreatic cancers epigenetically
silence SIP1 and hypomethylate and overexpress miR‑200a/200b
in association with elevated circulating miR‑200a and miR‑200b
levels. Cancer Res 70: 5226‑5237, 2010.
9. Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K,
Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K and
Satoh K: Circulating miR‑483‑3p and miR‑21 is highly expressed
in plasma of pancreatic cancer. Int J Oncol 46: 539‑547, 2015.
10. Panarelli NC, Chen YT, Zhou XK, Kitabayashi N and Yantiss RK:
MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas 41: 685‑690, 2012.
11. Hong TH and Park IY: MicroRNA expression profiling of
diagnostic needle aspirates from surgical pancreatic cancer
specimens. Ann Surg Treat Res 87: 290‑297, 2014.
12. Sadakari Y, Ohtsuka T, Ohuchida K, Tsutsumi K, Takahata S,
Nakamura M, Mizumoto K and Tanaka M: MicroRNA expression analyses in preoperative pancreatic juice samples of
pancreatic ductal adenocarcinoma. JOP 11: 587‑592, 2010.
13. Wang J, Raimondo M, Guha S, Chen J, Diao L, Dong X,
Wallace MB, Killary AM, Frazier ML, Woodward TA, et al:
Circulating microRNAs in pancreatic juice as candidate
biomarkers of pancreatic cancer. J Cancer 5: 696‑705, 2014.
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK,
Pogosova‑Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC,
Allen A, et al: Circulating microRNAs as stable blood‑based
markers for cancer detection. Proc Natl Acad Sci USA 105:
10513‑10518, 2008.
15. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and
Lötvall JO: Exosome‑mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between
cells. Nat Cell Biol 9: 654‑659, 2007.
16. Zhang J, Li S, Li L, Li M, Guo C, Yao J and Mi S: Exosome
and exosomal microRNA: Trafficking, sorting, and function.
Genomics Proteomics Bioinformatics 13: 17‑24, 2015.
17. Mlcochova H, Hezova R, Stanik M and Slaby O: Urine
microRNAs as potential noninvasive biomarkers in urologic
cancers. Urol Oncol 32: 41.e1‑e9, 2014.
18. Øverbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T,
Berge V, Sandvig K and Llorente A: Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget 6:
30357‑30376, 2015.
19. Franzen CA, Blackwell RH, Foreman KE, Kuo PC, Flanigan RC
and Gupta GN: Urinary exosomes: The potential for biomarker
utility, intercellular signaling and therapeutics in urological
malignancy. J Urol 195: 1331‑1339, 2016.
20. Conde‑Vancells J, Rodriguez‑Suarez E, Gonzalez E, Berisa A,
Gil D, Embade N, Valle M, Luka Z, Elortza F, Wagner C, et al:
Candidate biomarkers in exosome‑like vesicles purified from
rat and mouse urine samples. Proteomics Clin Appl 4: 416‑425,
2010.
21. Gildea JJ, Carlson JM, Schoeffel CD, Carey RM and Felder RA:
Urinary exosome miRNome analysis and its applications to salt
sensitivity of blood pressure. Clin Biochem 46: 1131‑1134, 2013.
22. Ballehaninna UK and Chamberlain RS: The clinical utility of
serum CA 19‑9 in the diagnosis, prognosis and management
of pancreatic adenocarcinoma: An evidence based appraisal.
J Gastrointest Oncol 3: 105‑119, 2012.
23. Stiksma J, Grootendorst DC and van der Linden PW: CA 19‑9 as
a marker in addition to CEA to monitor colorectal cancer. Clin
Colorectal Cancer 13: 239‑244, 2014.
24. Pandey D, Sharma R, Sharma S and Salhan S: Unusually high
serum levels of CA 19‑9 in an ovarian tumour: Malignant or
benign? J Clin Diagn Res 11: QD08‑QD10, 2017.
25. Debernardi S, Massat NJ, Radon TP, Sangaralingam A, Banissi A,
Ennis DP, Dowe T, Chelala C, Pereira SP, Kocher HM, et al:
Noninvasive urinary miRNA biomarkers for early detection of
pancreatic adenocarcinoma. Am J Cancer Res 5: 3455‑3466,
2015.
26. Kao HW, Pan CY, Lai CH, Wu CW, Fang WL, Huang KH and
Lin WC: Urine miR‑21‑5p as a potential non‑invasive biomarker
for gastric cancer. Oncotarget 8: 56389‑56397, 2017.
27. Yasui T, Yanagida T, Ito S, Konakade Y, Takeshita D, Naganawa T,
Nagashima K, Shimada T, Kaji N, Nakamura Y, et al: Unveiling
massive numbers of cancer‑related urinary‑microRNA candidates via nanowires. Sci Adv 3: e1701133, 2017.
28. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ,
Galas DJ and Wang K: The microRNA spectrum in 12 body
fluids. Clin Chem 56: 1733‑1741, 2010.
29. Brunetto GS, Massoud R, Leibovitch EC, Caruso B, Johnson K,
Ohayon J, Fenton K, Cortese I and Jacobson S: Digital
droplet PCR (ddPCR) for the precise quantification of human
T‑lymphotropic virus 1 proviral loads in peripheral blood and
cerebrospinal fluid of HAM/TSP patients and identification of
viral mutations. J Neurovirol 20: 341‑351, 2014.
30. Zhao S, Lin H, Chen S, Yang M, Yan Q, Wen C, Hao Z, Yan Y,
Sun Y, Hu J, et al: Sensitive detection of Porcine circovirus‑2 by
droplet digital polymerase chain reaction. J Vet Diagn Invest 27:
784‑788, 2015.
31. Pekin D, Skhiri Y, Baret JC, Le Corre D, Mazutis L, Salem CB,
Millot F, El Harrak A, Hutchison JB, Larson JW, et al:
Quantitative and sensitive detection of rare mutations using
droplet‑based microfluidics. Lab Chip 11: 2156‑2166, 2011.
32. Gutiérrez‑Aguirre I, Rački N, Dreo T and Ravnikar M: Droplet
digital PCR for absolute quantification of pathogens. Methods
Mol Biol 1302: 331‑347, 2015.
33. Conte D, Verri C, Borzi C, Suatoni P, Pastorino U, Sozzi G
and Fortunato O: Novel method to detect microRNAs using
chip‑based QuantStudio 3D digital PCR. BMC Genomics 16:
849, 2015.
34. Sun Y, Su B, Zhang P, Xie H, Zheng H, Xu Y, Du Q, Zeng H,
Zhou X, Chen C and Gao W: Expression of miR‑150 and
miR‑3940‑5p is reduced in non‑small cell lung carcinoma and
correlates with clinicopathological features. Oncol Rep 29:
704‑712, 2013.
35. Ren K, Li Y, Lu H, Li Z and Han X: miR‑3940‑5p functions as a
tumor suppressor in non‑small cell lung cancer cells by targeting
cyclin D1 and ubiquitin specific peptidase‑28. Transl Oncol 10:
80‑89, 2017.
This work is licensed under a Creative Commons
~ Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) License.
...
論文の公開元へ
